Potential for Drug Repositioning of Midazolam as an Inhibitor of Inflammatory Bone Resorption
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147651 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Hiroko Harigaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dental Anesthesiology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan. Hauptthemen laut MEDLINE: Bone Resorption, Drug Repositioning, Midazolam, Reactive Oxygen Species. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI.
Abstract (Originalsprache)
Drug repositioning is a method for exploring new effects of existing drugs, the safety and pharmacokinetics of which have been confirmed in humans. Here, we demonstrate the potential drug repositioning of midazolam (MDZ), which is used for intravenous sedation, as an inhibitor of inflammatory bone resorption. We cultured a mouse macrophage-like cell line with or without MDZ and evaluated its effects on the induction of differentiation of these cells into osteoclasts. For in vivo investigations, we administered lipopolysaccharide (LPS) together with MDZ (LPS+MDZ) to the parietal region of mice and evaluated the results based on the percentage of bone resorption and calvaria volume. Furthermore, we examined the effects of MDZ on the production of reactive oxygen species (ROS) in cells and on its signaling pathway. MDZ inhibited osteoclast differentiation and bone resorption activity. In animal studies, the LPS+MDZ group showed a decreasing trend associated with the rate of bone resorption. In addition, the bone matrix volume in the LPS+MDZ group was slightly higher than in the LPS only group. MDZ inhibited osteoclast differentiation by decreasing ROS production and thereby negatively regulating the p38 mitogen-activated protein kinase pathway. Thus, we propose that MDZ could potentially be used for treating inflammatory bone resorption, for example, in periodontal disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dental Anesthesiology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan.
- Department of Biochemistry and Molecular Biology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan.
ORCID-Profile: Yasuo Yamakoshi
Förderung
- Japan Society for the Promotion of Science
- JSPS KAKENHI
Zitieren
APA
Harigaya, H., Chiba-Ohkuma, R., Karakida, T., Yamamoto, R., Fujii-Abe, K., Kawahara, H., & Yamakoshi, Y. (2024). Potential for Drug Repositioning of Midazolam as an Inhibitor of Inflammatory Bone Resorption. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147651
Vancouver
Harigaya H, Chiba-Ohkuma R, Karakida T, Yamamoto R, Fujii-Abe K, Kawahara H, et al. Potential for Drug Repositioning of Midazolam as an Inhibitor of Inflammatory Bone Resorption. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147651
BibTeX
@article{Harigaya2024,
author = {Harigaya, Hiroko and Chiba-Ohkuma, Risako and Karakida, Takeo and Yamamoto, Ryuji and Fujii-Abe, Keiko and Kawahara, Hiroshi and Yamakoshi, Yasuo},
title = {Potential for Drug Repositioning of Midazolam as an Inhibitor of Inflammatory Bone Resorption},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147651}
}
EUVIMED